RhumbLine Advisers
SPRY icon

RhumbLine Advisers’s ARS Pharmaceuticals SPRY Stock Holding History

RhumbLine Advisers’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$609K Buy
75,989
+3,732
+5% +$32.1K ﹤0.01% 2639
2026
Q1 		$580K Sell
72,257
-1,036
-1% -$9.93K ﹤0.01% 2516
2025
Q4 		$854K Sell
73,293
-7,911
-10% -$76.9K ﹤0.01% 2321
2025
Q3 		$816K Sell
81,204
-57
-0.1% -$818 ﹤0.01% 2371
2025
Q2 		$1.42M Buy
81,261
+11,495
+16% +$166K ﹤0.01% 2070
2025
Q1 		$878K Buy
69,766
+4,603
+7% +$55.4K ﹤0.01% 2238
2024
Q4 		$687K Buy
65,163
+1,824
+3% +$25.5K ﹤0.01% 2462
2024
Q3 		$918K Sell
63,339
-2,603
-4% -$31K ﹤0.01% 2306
2024
Q2 		$561K Buy
65,942
+28,888
+78% +$256K ﹤0.01% 2592
2024
Q1 		$379K Buy
37,054
+726
+2% +$5.41K ﹤0.01% 2832
2023
Q4 		$199K Sell
36,328
-27
-0.1% -$118 ﹤0.01% 3192
2023
Q3 		$137K Buy
36,355
+1,924
+6% +$12.6K ﹤0.01% 3350
2023
Q2 		$231K Buy
+34,431
New +$230K ﹤0.01% 3165
2022
Q2 		– Sell
-24,075
Closed -$85K – 3226
2022
Q1 		$85K Buy
24,075
+2,833
+13% +$12.3K ﹤0.01% 2920
2021
Q4 		$141K Buy
21,242
+1,229
+6% +$9.99K ﹤0.01% 2897
2021
Q3 		$200K Buy
20,013
+3,333
+20% +$82.2K ﹤0.01% 2916
2021
Q2 		$515K Buy
16,680
+3,491
+26% +$112K ﹤0.01% 2556
2021
Q1 		$575K Buy
+13,189
New +$624K ﹤0.01% 2424

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RhumbLine Advisers's SPRY Position: Q2 2026 in Review

RhumbLine Advisers increased its ARS Pharmaceuticals (SPRY) stake by 5.2% in Q2 2026, buying an estimated $32.1K and bringing the position to 75,989 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #2639.

RhumbLine Advisers first reported a position in SPRY in Q1 2021 and has held it in 18 quarters since. The position peaked at $1.42M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • RhumbLine Advisers held 75,989 shares of ARS Pharmaceuticals worth $609K as of Q2 2026.
  • RhumbLine Advisers bought 3,732 ARS Pharmaceuticals shares in Q2 2026, an estimated $32.1K.
  • ARS Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2639 holding.
  • RhumbLine Advisers first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • RhumbLine Advisers's ARS Pharmaceuticals position peaked at $1.42M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.